Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Abstract Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been ob...

Full description

Bibliographic Details
Main Authors: Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery, Haitao Zhao
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Journal of Hematology & Oncology
Subjects:
Gastrointestinal malignancies
PD-1/PD-L1 blockade
Immune checkpoint inhibitor
Combination immunotherapy
Clinical application
Rationale
Online Access:http://link.springer.com/article/10.1186/s13045-019-0730-9

Internet

http://link.springer.com/article/10.1186/s13045-019-0730-9

Similar Items